Sapu003 in Advanced mTOR-sensitive Solid Tumors

NCT07369505 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer Metastatic
Renal Cell Carcinoma (RCC)
Neuroendocrine Tumors
Tuberous Sclerosis Complex (TSC)
Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Sapu003
DRUG: Exemestane 25 MG

Sponsor

SAPU NANO (US) LLC